Cleveland Clinic spinoff company NeuroTherapia Inc. will start clinical trials of a new drug targeting inflammation of the brain that’s found in Alzheimer’s and other neurological diseases, according to a news release.
The U.S. Food and Drug Administration gave the company the go-ahead to begin its first in-human studies of the drug, NTRX-07, in an ascending dose study schedule to begin midsummer.
Click here to read the complete article.
Story excerpt provided by Crain’s Cleveland Business.
Written by Lydia Coutre.
Originally published April 22, 2019.